Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EcNc-RtSOD
- Development stage
- Preclinical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Recombinant Proteins and Enzymes, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
EcNc-RtSOD is an engineered live biotherapeutic product (LBP) that utilizes the probiotic bacterium *Escherichia coli* Nissle 1917 (EcN) as a delivery chassis. The strain is modified with cryptic plasmids to constitutively express a superoxide dismutase (RtSOD), an antioxidant enzyme. Developed for the treatment of ulcerative colitis (UC), EcNc-RtSOD is designed to colonize the intestinal tract and provide a continuous supply of SOD directly to the inflamed mucosa. This localized delivery helps neutralize reactive oxygen species (ROS), thereby reducing oxidative stress and downregulating pro-inflammatory cytokines such as interleukin-6 (IL-6) and interleukin-1β (IL-1β). Preclinical studies in mouse models of colitis have demonstrated that treatment with EcNc-RtSOD significantly reduces intestinal inflammation, lowers malondialdehyde (MDA) levels, and promotes mucosal healing.
- Other names
- engineered Escherichia coli Nissle 1917 expressing RtSOD
Beyond the preview
Go deeper on EcNc-RtSOD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EcNc-RtSOD.